These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22323416)

  • 1. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial.
    Ramachandran A; Riddle MC; Kabali C; Gerstein HC;
    Diabetes Care; 2012 Apr; 35(4):749-53. PubMed ID: 22323416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.
    ORIGIN Trial Investigators
    Diabetes Care; 2013 Oct; 36(10):2915-22. PubMed ID: 23656980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis.
    Ma J; Lei M; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2020 Sep; 37(9):3816-3826. PubMed ID: 32671687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population.
    Badings EA; Dyal L; Schoterman L; Lok DJ; Stoel I; Gerding MN; Gerstein HC; Tijssen JG
    J Diabetes; 2011 Sep; 3(3):232-7. PubMed ID: 21631894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
    Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
    Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
    Li L; Yang T; Xue Y; Ruan P; Du J; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2022 Jan; 39(1):421-429. PubMed ID: 34757600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus.
    Garg SK; Aurand LA; Rimler MS; Dailey GE
    Endocr Pract; 2014 Feb; 20(2):120-8. PubMed ID: 24013981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FASTING VERSUS POSTPRANDIAL HYPERGLYCEMIA AS A TREATMENT TARGET TO LOWER ELEVATED HEMOGLOBIN A1C.
    Shaefer C; Reid T; Vlajnic A; Zhou R; DiGenio A
    Endocr Pract; 2015 Dec; 21(12):1323-32. PubMed ID: 26307902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
    Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
    Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
    J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
    Zinman B; Philis-Tsimikas A; Cariou B; Handelsman Y; Rodbard HW; Johansen T; Endahl L; Mathieu C;
    Diabetes Care; 2012 Dec; 35(12):2464-71. PubMed ID: 23043166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents.
    Heise T; Mathieu C; Hey-Hadavi J; Strack T; Lawrence D
    Diabetes Technol Ther; 2010 Feb; 12(2):135-41. PubMed ID: 20105043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.